Breast Cancer Management Panel

 
Test code: GDJ055

Related gene(s): ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, STK11, TP53

Test description:

This panel includes genes associated with increased risk to develop breast cancer, all with NCCN Guidelines® published for risk management.1-2 Identification of a pathogenic/likely pathogenic variant in these genes can help estimate cancer risk and guide treatment, screening, and/or prevention decisions for the patient.

Conditions:

  • Breast Cancer

 
Clinical utility:

  • Breast cancer diagnosed under 50 years of age
  • Multiple cancers in one person, either of the same origin (such as two separate breast cancers) or of different origins (such as breast cancer and ovarian cancer)
  • Ovarian cancer or male breast cancer at any age
  • Multiple relatives diagnosed with the same or related cancers (including breast, ovarian, pancreatic and/or prostate) on the same side of the family and spanning multiple generations
  • Ashkenazi Jewish ancestry with a history of breast, ovarian or pancreatic cancer

 
Lab method:

  • Deletion/duplication analysis
  • Next-Gen sequencing

Specimen Requirements

  • Preferred: 2-5 mL Blood – Lavender Top Tube
  • Alternative: Buccal Swabs, Fibroblasts (separate charge for cell culture may apply)

Ordering Information

  • CPT code(s):* 81162×1, 81321×1, 81323×1, 81406×1
  • Turnaround Time:* 2 weeks (8-10 days RUSH for surgical intervention)


*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
**Reporting times are typical and begin once the sample(s) are received at the GeneDx laboratory, but could be extended in situations outside GeneDx’s reasonable control.


Resources

Hereditary Cancer Requisition
Hereditary Cancer Re-requisition
GeneDx Test Information Sheet (TIS)



1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic V2.2021. National Comprehensive Cancer Network, Inc. 2021©. All rights reserved. Accessed,[5/18/2021]. To view the most recent and complete version of the guidelines, go online to NCCN.org.

2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Genetic/Familial High-Risk Assessment: Colorectal V1.2021. National Comprehensive Cancer Network, Inc. 2021©. All rights reserved. Accessed, [5/18/2021]. To view the most recent and complete version of the guidelines, go online to NCCN.org.